Drugs / TLN-499
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07713732 | Aug 2026 → Aug 2030 expected | malignant pleural mesothelioma, small cell lung carcinoma, synovial sarcoma | Treeline Biosciences, Inc. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TLN-499 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07713732 ↗ |